EXPONENT INC EXPO
Exponent, Inc., together with its subsidiaries, ("Exponent", the "Company", "we", "us" and "our") is a science and engineering consulting firm that provides solutions to complex problems. Our interdisciplinary team of scientists, physicians, engineers, and business consultants draws from more than 90 technical disciplines to solve the most pressing and complicated challenges facing stakeholders today. The firm leverages over 55 years of experience in analyzing accidents and failures to advise clients as they innovate their technologically complex products and processes, ensure the safety and health of their users, and address the challenges of sustainability.
The history of Exponent, Inc. goes back to 1967, with the founding of the partnership Failure Analysis Associates, which was incorporated the following year in California and reincorporated in Delaware as Failure Analysis Associates, Inc. in 1988. The Failure Group, Inc. was organized in 1989 as a holding company for Failure Analysis Associates, Inc. and changed its name to Exponent, Inc. in 1998.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $582.0M | $558.5M | $536.8M | $513.3M | $466.3M | $399.9M | $417.2M | $379.5M | $347.8M | $315.1M |
| SG&A | $25.5M | $22.7M | $24.4M | $23.7M | $15.3M | $12.9M | $20.5M | $17.5M | $17.8M | $15.5M |
| Total operating expenses | $462.2M | $439.0M | $425.4M | $372.5M | $357.3M | $316.7M | $332.1M | $288.1M | $275.7M | $253.2M |
| Operating income | $119.8M | $119.6M | $111.3M | $140.8M | $108.9M | $83.2M | $85.1M | $91.5M | $72.1M | $61.9M |
| Pre-tax income | $147.3M | $147.4M | $135.9M | $132.2M | $125.8M | $96.9M | $104.2M | $93.3M | $82.5M | $69.1M |
| Income tax | $41.3M | $38.4M | $35.6M | $29.9M | $24.6M | $14.4M | $21.7M | $21.1M | $41.2M | $21.6M |
| Net income | $106.0M | $109.0M | $100.3M | $102.3M | $101.2M | $82.6M | $82.5M | $72.3M | $41.3M | $47.5M |
| EPS, basic | 2.08 | 2.13 | 1.96 | 1.98 | 1.92 | 1.58 | 1.56 | 1.37 | 0.78 | 0.90 |
| EPS, diluted | 2.07 | 2.11 | 1.94 | 1.96 | 1.90 | 1.55 | 1.53 | 1.33 | 0.77 | 0.87 |
| Shares, diluted (wtd. avg.) | $51.2M | $51.6M | $51.6M | $52.3M | $53.3M | $53.3M | $53.9M | $54.2M | $54.0M | $54.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $221.9M | $258.9M | $187.2M | $161.5M | $297.7M | $197.5M | $176.4M | $127.1M | $124.8M | $115.0M |
| Short-term investments | — | — | — | — | — | $45.0M | $55.2M | $81.5M | $71.6M | $58.8M |
| Receivables | $181.5M | $161.4M | $167.4M | $170.1M | $139.9M | $111.6M | $120.1M | $105.8M | $110.1M | $87.4M |
| Total current assets | $427.6M | $446.9M | $379.5M | $349.2M | $452.8M | $366.8M | $364.0M | $326.6M | $315.5M | $274.0M |
| Property, plant and equipment | $72.0M | $73.0M | $75.3M | $65.5M | $60.0M | $59.8M | $61.6M | $46.1M | $35.0M | $36.7M |
| Goodwill | $8.6M | $8.6M | $8.6M | $8.6M | $8.6M | $8.6M | $8.6M | $8.6M | $8.6M | $8.6M |
| Total assets | $777.5M | $777.3M | $646.8M | $586.7M | $683.7M | $580.1M | $563.4M | $468.9M | $439.6M | $403.7M |
| Accounts payable | $6.9M | $5.3M | $4.5M | $8.6M | $3.2M | $3.3M | $4.6M | $2.6M | $2.8M | $3.2M |
| Total current liabilities | $178.0M | $163.2M | $161.9M | $159.0M | $153.0M | $117.3M | $124.0M | $98.3M | $93.1M | $80.2M |
| Total liabilities | $387.2M | $356.2M | $290.7M | $265.9M | $266.7M | $218.6M | $213.2M | $155.0M | $150.5M | $130.4M |
| Retained earnings | $668.4M | $624.2M | $574.1M | $528.8M | $478.4M | $421.8M | $384.7M | $342.0M | $304.0M | $291.2M |
| Total equity | $390.3M | $421.1M | $356.1M | $320.8M | $417.1M | $361.5M | $350.3M | $313.9M | $289.1M | $273.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $131.7M | $144.5M | $127.4M | $93.8M | $124.6M | $103.3M | $108.1M | $91.2M | $67.8M | $66.9M |
| Stock-based compensation | $23.8M | $23.2M | $20.4M | $20.4M | $19.3M | $17.3M | $17.5M | $17.0M | $16.2M | $13.3M |
| Capital expenditure | $9.4M | $6.9M | $16.4M | $12.0M | $6.8M | $5.0M | $23.0M | $16.3M | $4.7M | $14.4M |
| Investing cash flow | -$9.4M | -$6.9M | -$16.4M | -$12.0M | $38.2M | $5.0M | $4.3M | -$25.8M | -$17.7M | -$27.4M |
| Financing cash flow | -$160.4M | -$65.1M | -$86.0M | -$216.0M | -$62.8M | -$88.4M | -$63.4M | -$62.5M | -$41.3M | -$49.2M |
| Dividends paid | $60.4M | $56.8M | $54.0M | $49.2M | $43.2M | $39.8M | $33.5M | $27.2M | $21.8M | $18.8M |
| Buybacks | $97.1M | $5.7M | $24.2M | $155.9M | $7.0M | $40.0M | $22.0M | $27.9M | $11.9M | $24.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-163945.
Others in SIC 8742
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| BAH | Booz Allen Hamilton Holding Corp | $8.76B | 10.6x | -6.4% |
| G | Genpact LTD | $6.27B | 11.9x | 6.6% |
| FCN | FTI CONSULTING, INC | $4.19B | 18.4x | 2.4% |
| HURN | Huron Consulting Group Inc. | $2.52B | 26.6x | 11.9% |
| ASTH | Astrana Health, Inc. | $2.14B | 83.6x | 56.4% |
| ICFI | ICF International, Inc. | $1.58B | 17.8x | -7.3% |
| BWMN | Bowman Consulting Group Ltd. | $735.5M | 58.1x | 14.9% |
| ONT | Onterris, Inc. | $626.8M | — | 19.3% |